RxDoctor Payments Data

Ellis Easterling, MD

Hospitalist · Sioux Falls, SDNPI 1508286931

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.9% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boehringer Ingelheim at 40.7% of the total. Reporting peaked in 2019 at $140 and has fallen 74.6% since, to $36 in 2023.

$220in general payments, 2019–2025

Across 13 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$90
  • Vifor Pharma, Inc.$52
  • Abbott$20
  • AbbVie$17
  • Novo Nordisk$16
  • Pfizer$14
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$20091%
  • Other$209%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$220 in reported general payments places this provider in the 85th percentile of 81 hospitalist providers in South Dakota.

See all hospitalist providers in South Dakota

Medicare billing

Part B allowed, 2024
$64,454
Medicare patients
516
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$29,769
XareltoRivaroxaban28$26,255
JardianceEmpagliflozin16$18,906
Tresiba Flextouch U-100Insulin Degludec20$13,901
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$12,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,713
JanuviaSitagliptin Phosphate13$10,650
Atorvastatin Calcium304$2,330
Tamsulosin Hcl116$1,748
Rosuvastatin Calcium134$1,718
Omeprazole183$1,671
Ultra-Fine Short Pen NeedlePen Needle, Diabetic16$1,599
Metoprolol Succinate98$1,496
Fentanyl14$1,420
Levothyroxine Sodium140$1,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$29,76930 claims
Johnson & JohnsonXarelto$12$26,25528 claims
Boehringer IngelheimJardiance$90$18,90616 claims
AbbVieSynthroid$17$44811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 81 hospitalist providers in South Dakota.

Other hospitalist in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →